Endocrine complications are common in pediatric brain tumor patients.To describe hypothalamic-pituitary-gonadal axis (HPGA) function in patients treated in childhood for a primary brain tumor more than 5 years earlier, in order to identify risk factors for HPGA impairment.We retrospectively included 204 patients diagnosed with a primary brain tumor before 18 years of age and monitored at the pediatric endocrinology unit of the Necker Enfants-Malades University Hospital (Paris, France) between January 2010 and December 2015. Patients with pituitary adenoma or untreated glioma were excluded.Among patients with suprasellar glioma not treated by radiotherapy, the prevalence of advanced puberty was 65% overall and 70% when the diagnosis occurred before 5 years of age. Medulloblastoma chemotherapy caused gonadal toxicity in 70% of all patients and in 87.5% of those younger than 5 years at diagnosis. In the group with craniopharyngioma, 70% of patients had hypogonadotropic hypogonadism, which was consistently accompanied by growth hormone deficiency.Tumor type, location, and treatment were the risk main factors for HPGA impairment. Awareness that onset can be delayed is essential to guide information of parents and patients, patient monitoring, and timely hormone replacement therapy.
Immunoassays are powerful qualitative and quantitative analytical techniques. Since the first description of an immunoassay method in 1959, advances have been made in assay designs and analytical characteristics, opening the door for their widespread implementation in clinical laboratories. Clinical endocrinology is closely linked to laboratory medicine because hormone quantification is important for the diagnosis, treatment, and prognosis of endocrine disorders. Several interferences in immunoassays have been identified through the years; although some are no longer encountered in daily practice, cross-reaction, heterophile antibodies, biotin, and anti-analyte antibodies still cause problems. Newer interferences are also emerging with the development of new therapies. The interfering substance may be exogenous (e.g., a drug or substance absorbed by the patient) or endogenous (e.g., antibodies produced by the patient), and the bias caused by interference can be positive or negative. The consequences of interference can be deleterious when clinicians consider erroneous results to establish a diagnosis, leading to unnecessary explorations or inappropriate treatments. Clinical laboratories and manufacturers continue to investigate methods for the detection, elimination, and prevention of interferences. However, no system is completely devoid of such incidents. In this review, we focus on the analytical interferences encountered in daily practice and possible solutions for their detection or elimination.
Journal Article Accepted manuscript Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring Get access A Galderisi, A Galderisi Yale University, Pediatrics; Hopital Necker-Enfants, Malades, Pediatrics Corresponding author: Email: alfonso.galderisi@yale.edu, alfonsogalderisi@gmail.com https://orcid.org/0000-0001-8885-3056 Search for other works by this author on: Oxford Academic Google Scholar D Kariyawasam, D Kariyawasam HP Centre, Department of Paediatric Endocrinology; Université Paris Cité, Pediatrie; Université Sorbonne Paris Cité, Pediatrie Search for other works by this author on: Oxford Academic Google Scholar A Stoupa, A Stoupa Hopital universitaire Necker-Enfants malades, Paediatric Endocrinology, Diabetology and Gynaecology Department Nguyen Search for other works by this author on: Oxford Academic Google Scholar A Quoc, A Quoc Hôpital Universitaire Necker-Enfants Malades, Pediatric endocrinology https://orcid.org/0000-0002-1601-156X Search for other works by this author on: Oxford Academic Google Scholar G Pinto, G Pinto Hôpital universitaire Necker-Enfants malades, Pediatric Endocrinology, Gynecology and Diabetology Unit https://orcid.org/0000-0002-5237-0631 Search for other works by this author on: Oxford Academic Google Scholar M Viaud, M Viaud Hopital universitaire Necker-Enfants malades, Endocrinology, diabetology and gynecology unit Search for other works by this author on: Oxford Academic Google Scholar S Brabant, S Brabant APHP, Laboratoire d'Explorations Fonctionnelles, Hôpital Necker-Enfants Malades, AP-HP Centre Université de Paris, Paris, France Search for other works by this author on: Oxford Academic Google Scholar J Beltrand, J Beltrand Hopital universitaire Necker-Enfants malades, Paediatric Endocrinology, Diabetology and Gynaecology Department; Université Sorbonne Paris Cité, Faculté de Médecine; Institut Cochin, INSERM U1016; Institut Imagine Institut des Maladies Genetiques, Affiliate INSERM U1163 https://orcid.org/0000-0002-3759-3490 Search for other works by this author on: Oxford Academic Google Scholar M Polak, M Polak Hôpital universitaire Necker-Enfants malades, Pediatric endocrinology gynecology and diabetology Search for other works by this author on: Oxford Academic Google Scholar D Samara-Boustani D Samara-Boustani Samara-Boustani, Dinane; Hopital universitaire Necker-Enfants malades, Service d'Endocrinologie et Diabétologie pédiatrique https://orcid.org/0000-0002-1135-933X Search for other works by this author on: Oxford Academic Google Scholar European Journal of Endocrinology, lvae042, https://doi.org/10.1093/ejendo/lvae042 Published: 26 April 2024 Article history Received: 13 March 2024 Accepted: 20 March 2024 Published: 26 April 2024
